Trevi Therapeutics, Inc. · NASDAQ:TRVI
James N. Topper reported a 11.90% stake in Trevi Therapeutics, Inc. (Schedule 13G/A)
Event Dec 31, 2024 · Filed Feb 14, 2025
James N. Topper reported a 11.90% stake in Trevi Therapeutics, Inc., 10,664,774 shares, as a passive investor on Dec 31, 2024. Filed Feb 14, 2025 (Schedule 13G/A).
- Stake
- 11.90%
- Shares
- 10,664,774
- Intent
- Passive
- What changed
- Stake changed
- Filed together
- 14 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| Frazier Life Sciences Public Fund, L.P. | 9.90% | 8,819,620 |
| FHMLSP, L.P. | 9.90% | 8,819,620 |
| FHMLSP, L.L.C. | 9.90% | 8,819,620 |
| Frazier Life Sciences X, L.P. | 0.50% | 428,000 |
| FHMLS X, L.P. | 0.50% | 428,000 |
| FHMLS X, L.L.C. | 0.50% | 428,000 |
| Frazier Life Sciences XI, L.P. | 1.60% | 1,417,154 |
| FHMLS XI, L.P. | 1.60% | 1,417,154 |
| FHMLS XI, L.L.C. | 1.60% | 1,417,154 |
| James N. Topper | 11.90% | 10,664,774 |
| Patrick J. Heron | 11.90% | 10,664,774 |
| Albert Cha | 9.90% | 8,819,620 |
| James Brush | 9.90% | 8,819,620 |
| Daniel Estes | 1.60% | 1,417,154 |
Source
Related
- Trevi Therapeutics, Inc.
- Frazier Life Sciences Public Fund, L.P.
- Trevi Therapeutics, Inc. shareholders
- Schedule 13G/A · Frazier Life Sciences Public Fund, L.P. · Nov 14, 2025
- Schedule 13G/A · Frazier Life Sciences Public Fund, L.P. · May 15, 2025
- Form 4 · Heffernan Michael Thomas · Sep 17, 2026
- Schedule 13G/A · FMR LLC · Aug 6, 2026
- Schedule 13D/A · New Enterprise Associates 16, L.P. · May 7, 2026
- Schedule 13G/A · FMR LLC · May 6, 2026
- Schedule 13G/A · The Vanguard Group · Mar 27, 2026